Interventional × Sarcoma, Synovial × Imatinib Mesylate × Clear all
NCT00154388 2016-11-18

Phase II Study of Imatinib Mesylate in Patients With Life Threatening Malignant Rare Diseases

Novartis

Phase 2 Completed
185 enrolled
NCT00006357 2012-09-24

STI571 in Treating Patients With Recurrent or Refractory Soft Tissue Sarcoma

European Organisation for Research and Treatment of Cancer - EORTC

Phase 1/2 Completed
91 enrolled